The grumbling concerns and problems with dabigatran, including haemorrhagic complications, lack of a tidy reversal agent and widespread off-label use and associated problems are well summarised in Ryan Radecki’s (of emlitofnote.com) opinion article in Annals of IM here.
- RT @ACTINOSProject: Great, hard writing from @BarnsGreg, as ever. The terrible things being done in our name are being done because collect… 2 weeks ago
- Do @thetopend such dodgy coverage...can't get it back 1 month ago
- @TheTopEnd are you coming to Hobart, Doug? I expect a call if so! 1 month ago